A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue.
OBJECTIVE
To test the antitumour effect of gonadotrophin releasing-hormone (GnRH) analogues in women with recurrent endometrial cancer.


METHODS
An open phase II observational trial of GnRH analogues. Serial measurements of gonadotrophins, sex hormones and tumour dimensions were made together with repeat biopsy when possible to assess the response to treatment.


METHODS
The outpatient clinics of the Department of Medical Oncology at The Royal London, Royal Marsden and St Bartholomew's hospitals.


METHODS
17 patients with endometrial cancer which had recurred after surgery, radiotherapy and progesterone treatment and was symptomatic, progressive and assessable for response.


METHODS
Monthly subcutaneous injection of GnRH analogue.


METHODS
Reduction in serum gonadotrophins and reduction in tumour dimensions.


RESULTS
Six out of 17 patients (35%, 95% CI 12.6-58%) achieved a complete or partial remission which continues for a median of 20 months with no adverse effects.


CONCLUSIONS
GnRH analogues have a significant antitumour effect in recurrent endometrial cancer which warrants further examination in comparison with progestogens.
Gallagher
C J
CJ
Department of Medical Oncology, Royal London Hospital.
Oliver
R T
RT
Oram
D H
DH
Fowler
C G
CG
Blake
P R
PR
Mantell
B S
BS
Slevin
M L
ML
Hope-Stone
H F
HF
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D016889:Endometrial Neoplasms / Q000188:drug therapy*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000031:analogs & derivatives*; D006801:Humans; D008875:Middle Aged; D011379:Prognosis
D007987:Gonadotropin-Releasing Hormone